跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 11,708 条关于
“G/GEJ adenocarcinoma”
全部
11,708
临床试验
9,075
药物
857
机构
101
资讯
1,675
去年
Claudin 18.2-Targeted Therapies Show Promise in Gastric and Other Cancers
去年
IBI343 Shows Promising Efficacy in CLDN18.2-Positive Gastric Cancer with Improved Safety Profile
去年
Vyloy Leads Claudin 18.2 Targeted Therapy Revolution with 60+ Drug Candidates in Pipeline
去年
Pembrolizumab Plus Chemotherapy Improves Overall Survival in HER2-Positive Gastric Cancer
去年
SOXRC Regimen Enhances Responses in Advanced Gastric Cancer
去年
FDA Approves Tevimbra Plus Chemotherapy for First-Line Treatment of Gastric and GEJ Adenocarcinoma
去年
Cadonilimab Plus Chemotherapy Shows Survival Benefit in Advanced Gastric Cancer
去年
FDA Approves Zolbetuximab for CLDN18.2-Positive Gastric and GEJ Adenocarcinoma
去年
FDA Approves Zolbetuximab for CLDN18.2-Positive Gastric and GEJ Adenocarcinoma
去年
FDA Approves Zolbetuximab for CLDN18.2-Positive Gastric and GEJ Adenocarcinoma
第 1 页,共 168 页
上一页
下一页